Key Insights

Highlights

Success Rate

95% trial completion (above average)

Published Results

122 trials with published results (14%)

Research Maturity

602 completed trials (68% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

3.5%

31 terminated out of 887 trials

Success Rate

95.1%

+8.6% vs benchmark

Late-Stage Pipeline

14%

122 trials in Phase 3/4

Results Transparency

20%

122 of 602 completed with results

Key Signals

122 with results95% success31 terminated

Data Visualizations

Phase Distribution

632Total
Not Applicable (235)
Early P 1 (4)
P 1 (147)
P 2 (124)
P 3 (70)
P 4 (52)

Trial Status

Completed602
Unknown120
Recruiting63
Terminated31
Active Not Recruiting24
Not Yet Recruiting23

Trial Success Rate

95.1%

Benchmark: 86.5%

Based on 602 completed trials

Clinical Trials (887)

Showing 20 of 20 trials
NCT07124559Phase 1Not Yet RecruitingPrimary

A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV

NCT06739915Not ApplicableCompleted

Targeted Universal TB Testing With Simultaneous TPT Prescribing Among People Living With HIV in South Africa

NCT06054334CompletedPrimary

Relevance of Isoniazid Dosage in Adults Treated for Tuberculosis

NCT06893757RecruitingPrimary

Prospective Cohort of People Starting Treatment for Tuberculosis Disease in France (FrenchTB)

NCT04926922CompletedPrimary

PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia

NCT07638670RecruitingPrimary

Effect of Mycobacterial Infection on Immune Status

NCT05473520Phase 3RecruitingPrimary

Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis

NCT01212003Recruiting

Training Protocol on the Natural History of Tuberculosis

NCT05824091Phase 1CompletedPrimary

Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults

NCT07332325Phase 3Not Yet Recruiting

STeroids and Enhanced Spectrum Antibiotics for the Treatment of Patients in Africa With Refractory Sepsis

NCT06253715Phase 3RecruitingPrimary

Shortened Regimen for Drug-susceptible TB in Children

NCT00164281Phase 4CompletedPrimary

Study of Limited Versus Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana

NCT07609264Not Yet Recruiting

TB Stigma in the UK: Patients Experiences and Everyday Responses

NCT07607288Enrolling By Invitation

Collect Data From Patients Receiving Standardized Anti-tuberculosis Therapy, Collect Monitoring Data, and Evaluate Treatment Efficacy and Potential Adverse Reactions.

NCT05342064Not ApplicableActive Not RecruitingPrimary

Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered Service

NCT05586230Phase 1CompletedPrimary

Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis

NCT07595042Phase 2Not Yet RecruitingPrimary

A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB)

NCT04230395Not ApplicableActive Not RecruitingPrimary

Alcohol Reduction Among People With TB and HIV in India

NCT04303104Not ApplicableCompletedPrimary

Xpert Active Case-finding Trial 3 (XACT-3)

NCT05220163Not ApplicableActive Not RecruitingPrimary

Evaluating the Impact of Computer-assisted X-ray Diagnosis and Other Triage Tools to Optimise Xpert Orientated Community-based Active Case Finding for TB and COVID-19

Scroll to load more

Research Network

Activity Timeline